Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs
Abstract Background The patterns and determinants of saxagliptin use among patients with type 2 diabetes mellitus (T2DM) are unknown in real-world settings. We compared the characteristics of T2DM patients who were new initiators of saxagliptin to those who were new initiators of non-dipeptidyl pept...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2015-04-01
|
| Series: | BMC Pharmacology and Toxicology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40360-015-0007-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849730881029144576 |
|---|---|
| author | M Elle Saine Dean M Carbonari Craig W Newcomb Melissa S Nezamzadeh Kevin Haynes Jason A Roy Serena Cardillo Sean Hennessy Crystal N Holick Daina B Esposito Arlene M Gallagher Harshvinder Bhullar Brian L Strom Vincent Lo Re |
| author_facet | M Elle Saine Dean M Carbonari Craig W Newcomb Melissa S Nezamzadeh Kevin Haynes Jason A Roy Serena Cardillo Sean Hennessy Crystal N Holick Daina B Esposito Arlene M Gallagher Harshvinder Bhullar Brian L Strom Vincent Lo Re |
| author_sort | M Elle Saine |
| collection | DOAJ |
| description | Abstract Background The patterns and determinants of saxagliptin use among patients with type 2 diabetes mellitus (T2DM) are unknown in real-world settings. We compared the characteristics of T2DM patients who were new initiators of saxagliptin to those who were new initiators of non-dipeptidyl peptidase-4 (DPP-4) inhibitor oral anti-diabetic drugs (OADs) and identified factors associated with saxagliptin use. Methods We conducted a cross-sectional study within the Clinical Practice Research Datalink (CPRD), The Health Improvement Network (THIN), US Medicare, and the HealthCore Integrated Research Database (HIRDSM) across the first 36 months of saxagliptin availability (29 months for US Medicare). Patients were included if they were: 1) ≥18 years old, 2) newly prescribed saxagliptin or a non-DPP-4 inhibitor OAD, and 3) enrolled in their respective database for 180 days. For each saxagliptin initiator, we randomly selected up to ten non-DPP-4 inhibitor OAD initiators matched on age, sex, and geographic region. Conditional logistic regression was used to identify determinants of saxagliptin use. Results We identified 64,079 saxagliptin initiators (CPRD: 1,962; THIN: 2,084; US Medicare: 51,976; HIRDSM: 8,057) and 610,660 non-DPP-4 inhibitor OAD initiators (CPRD: 19,484; THIN: 19,936; US Medicare: 493,432; HIRDSM: 77,808). Across all four data sources, prior OAD use, hypertension, and hyperlipidemia were associated with saxagliptin use. Saxagliptin initiation was also associated with hemoglobin A1c results >8% within the UK data sources, and a greater number of hemoglobin A1c measurements in the US data sources. Conclusions In these UK and US data sources, initiation of saxagliptin was associated with prior poor glycemic control, prior OAD use, and diagnoses of hypertension and hyperlipidemia. Trial registration ClinicalTrials.gov identifiers NCT01086280 , NCT01086293 , NCT01086319 , NCT01086306 , and NCT01377935 |
| format | Article |
| id | doaj-art-2d1f567b51f548658000072312263efa |
| institution | DOAJ |
| issn | 2050-6511 |
| language | English |
| publishDate | 2015-04-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Pharmacology and Toxicology |
| spelling | doaj-art-2d1f567b51f548658000072312263efa2025-08-20T03:08:44ZengBMCBMC Pharmacology and Toxicology2050-65112015-04-0116111610.1186/s40360-015-0007-zDeterminants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugsM Elle Saine0Dean M Carbonari1Craig W Newcomb2Melissa S Nezamzadeh3Kevin Haynes4Jason A Roy5Serena Cardillo6Sean Hennessy7Crystal N Holick8Daina B Esposito9Arlene M Gallagher10Harshvinder Bhullar11Brian L Strom12Vincent Lo Re13Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of PennsylvaniaDepartment of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of PennsylvaniaDepartment of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of PennsylvaniaDepartment of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of PennsylvaniaDepartment of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of PennsylvaniaDepartment of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of PennsylvaniaDepartment of Medicine, Perelman School of Medicine at the University of PennsylvaniaDepartment of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of PennsylvaniaHealthCore, IncHealthCore, IncClinical Practice Research Datalink, Medicines and Healthcare Products Regulatory AgencyCegedim Strategic Data Medical ResearchDepartment of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of PennsylvaniaDepartment of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of PennsylvaniaAbstract Background The patterns and determinants of saxagliptin use among patients with type 2 diabetes mellitus (T2DM) are unknown in real-world settings. We compared the characteristics of T2DM patients who were new initiators of saxagliptin to those who were new initiators of non-dipeptidyl peptidase-4 (DPP-4) inhibitor oral anti-diabetic drugs (OADs) and identified factors associated with saxagliptin use. Methods We conducted a cross-sectional study within the Clinical Practice Research Datalink (CPRD), The Health Improvement Network (THIN), US Medicare, and the HealthCore Integrated Research Database (HIRDSM) across the first 36 months of saxagliptin availability (29 months for US Medicare). Patients were included if they were: 1) ≥18 years old, 2) newly prescribed saxagliptin or a non-DPP-4 inhibitor OAD, and 3) enrolled in their respective database for 180 days. For each saxagliptin initiator, we randomly selected up to ten non-DPP-4 inhibitor OAD initiators matched on age, sex, and geographic region. Conditional logistic regression was used to identify determinants of saxagliptin use. Results We identified 64,079 saxagliptin initiators (CPRD: 1,962; THIN: 2,084; US Medicare: 51,976; HIRDSM: 8,057) and 610,660 non-DPP-4 inhibitor OAD initiators (CPRD: 19,484; THIN: 19,936; US Medicare: 493,432; HIRDSM: 77,808). Across all four data sources, prior OAD use, hypertension, and hyperlipidemia were associated with saxagliptin use. Saxagliptin initiation was also associated with hemoglobin A1c results >8% within the UK data sources, and a greater number of hemoglobin A1c measurements in the US data sources. Conclusions In these UK and US data sources, initiation of saxagliptin was associated with prior poor glycemic control, prior OAD use, and diagnoses of hypertension and hyperlipidemia. Trial registration ClinicalTrials.gov identifiers NCT01086280 , NCT01086293 , NCT01086319 , NCT01086306 , and NCT01377935https://doi.org/10.1186/s40360-015-0007-zDiabetes mellitusSaxagliptinDipeptidyl peptidase IV inhibitorPharmacoepidemiology |
| spellingShingle | M Elle Saine Dean M Carbonari Craig W Newcomb Melissa S Nezamzadeh Kevin Haynes Jason A Roy Serena Cardillo Sean Hennessy Crystal N Holick Daina B Esposito Arlene M Gallagher Harshvinder Bhullar Brian L Strom Vincent Lo Re Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs BMC Pharmacology and Toxicology Diabetes mellitus Saxagliptin Dipeptidyl peptidase IV inhibitor Pharmacoepidemiology |
| title | Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs |
| title_full | Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs |
| title_fullStr | Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs |
| title_full_unstemmed | Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs |
| title_short | Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs |
| title_sort | determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti diabetic drugs |
| topic | Diabetes mellitus Saxagliptin Dipeptidyl peptidase IV inhibitor Pharmacoepidemiology |
| url | https://doi.org/10.1186/s40360-015-0007-z |
| work_keys_str_mv | AT mellesaine determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs AT deanmcarbonari determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs AT craigwnewcomb determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs AT melissasnezamzadeh determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs AT kevinhaynes determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs AT jasonaroy determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs AT serenacardillo determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs AT seanhennessy determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs AT crystalnholick determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs AT dainabesposito determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs AT arlenemgallagher determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs AT harshvinderbhullar determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs AT brianlstrom determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs AT vincentlore determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs |